Evaluasi Penggunaan Ramipril dan Candesartan pada Pasien Rawat Inap COVID-19 dengan Komorbid Hipertensi di RSUD Dr. Moewardi

Deva Yolanda Dwi Nur Azizah, Tri Wijayanti, Lukito Mindi Cahyo
2023 Jurnal Kefarmasian Indonesia  
Hypertension is the most common comorbid in patients infected by COVID-19. Drugs often given for the treatment of hypertension, namely ramipril, and candesartan, are thought to increase the development of COVID-19 because the angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) increase the expression of ACE-2, which is the binding site of SARS-CoV-2. This study aims to analyze the effect of using ramipril and candesartan on healing in hospitalized patients
more » ... th COVID-19 with hypertension at RSUD dr. Moewardi in 2020. This study was conducted retrospectively. The results were presented descriptively and used medical record data of hospitalized patients with COVID-19 with comorbid hypertension at RSUD dr. Moewardi in 2020. Using ramipril and candesartan affects patient recovery in terms of length of stay (LOS), symptom relief, and RT-PCR test results. Analysis of the research data using SPSS with Spearman correlation test. The Spearman correlation test showed that there was a fairly strong relationship between the use of ramipril and candesartan in patients with COVID-19 with comorbid hypertension on LOS, symptom relief, and RT-PCR test results. The study results show that using ramipril and candesartan can improve the recovery of patients with COVID-19 with comorbid hypertension. ACEI and ARB drugs have not been proven to worsen the patient's condition so their use can be continued.
doi:10.22435/jki.v13i1.6064 fatcat:hya2cbxvizaanhqssap4zsmnuu